Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

Dosed second patient in the SUNRISE-PD phase 2

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
georgejjl Member Profile
 
Followed By 80
Posts 11,755
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
georgejjl   Friday, 02/22/19 01:10:46 PM
Re: None
Post # of 754 
Quote:
Dosed second patient in the SUNRISE-PD phase 2 clinical trial of AXO-Lenti-PD in November 2018, with data expected in March 2019



Good luck and GOD bless,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist